Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR — Helsinn

  • Akynzeo®oral (Netupitant and Palonosetron hydrochloride) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and with moderately emetogenic cancer chemotherapy
  • anamorelin, a selective, novel, orally active ghrelin receptor agonist, which is being developed for the treatment of Malignancy Associated Weight Loss and Anorexia in non-small cell lung cancer patients



Swiss-Italian Pharmaceutical Entrepreneur Riccardo Braglia

Love podcasts or audiobooks? Learn on the go with our new app.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store